PF 05206388
Alternative Names: Human embryonic stem cell derived retinal pigment epithelium - Pfizer; PF-05206388; PF-5206388Latest Information Update: 28 Sep 2024
At a glance
- Originator Pfizer; University College London
- Class Cell therapies; Eye disorder therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Wet age-related macular degeneration
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Wet age-related macular degeneration(In the elderly) in United Kingdom (Intraocular, Implant)
- 02 Sep 2022 Phase I development is still ongoing in United Kingdom (NCT01691261)
- 22 Aug 2022 University College re-initiates enrolment in a phase-I clinical trials in Wet age-related macular degeneration (In the elderly) in United Kingdom (Intraocular; Implant) (NCT01691261)